228 related articles for article (PubMed ID: 23177280)
1. Hepatitis C viral kinetics: the past, present, and future.
Chatterjee A; Smith PF; Perelson AS
Clin Liver Dis; 2013 Feb; 17(1):13-26. PubMed ID: 23177280
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Guedj J; Dahari H; Shudo E; Smith P; Perelson AS
Hepatology; 2012 Apr; 55(4):1030-7. PubMed ID: 22095398
[TBL] [Abstract][Full Text] [Related]
3. Silymarin for HCV infection.
Polyak SJ; Oberlies NH; Pécheur EI; Dahari H; Ferenci P; Pawlotsky JM
Antivir Ther; 2013; 18(2):141-7. PubMed ID: 23011959
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
Chatterjee A; Guedj J; Perelson AS
Antivir Ther; 2012; 17(6 Pt B):1171-82. PubMed ID: 23186606
[TBL] [Abstract][Full Text] [Related]
5. Excitement grows for potential revolution in hepatitis C virus treatment.
Opar A
Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
[No Abstract] [Full Text] [Related]
6. Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.
Chacko KR; Gaglio PJ
Clin Liver Dis; 2015 Nov; 19(4):605-17, v. PubMed ID: 26466650
[TBL] [Abstract][Full Text] [Related]
7. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
8. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
[TBL] [Abstract][Full Text] [Related]
9. [Hepatitis C virus: therapeutic targets and new drugs].
Nikolaeva LI; Sapronov GV
Vopr Virusol; 2012; 57(5):10-5. PubMed ID: 23248853
[TBL] [Abstract][Full Text] [Related]
10. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
11. HCV protease inhibitors bring new options for patients.
Traynor K
Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
[No Abstract] [Full Text] [Related]
12. Understanding silibinin's modes of action against HCV using viral kinetic modeling.
Guedj J; Dahari H; Pohl RT; Ferenci P; Perelson AS
J Hepatol; 2012 May; 56(5):1019-1024. PubMed ID: 22245888
[TBL] [Abstract][Full Text] [Related]
13. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
Pár A
Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
[TBL] [Abstract][Full Text] [Related]
14. A review of HCV protease inhibitors.
Chen KX; Njoroge FG
Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
[TBL] [Abstract][Full Text] [Related]
15. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Nelson DR
Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
[TBL] [Abstract][Full Text] [Related]
16. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.
Rong L; Perelson AS
Crit Rev Immunol; 2010; 30(2):131-48. PubMed ID: 20370626
[TBL] [Abstract][Full Text] [Related]
18. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.
Guedj J; Perelson AS
Hepatology; 2011 Jun; 53(6):1801-8. PubMed ID: 21384401
[TBL] [Abstract][Full Text] [Related]
19. Anti-HCV drugs in the pipeline.
Yang PL; Gao M; Lin K; Liu Q; Villareal VA
Curr Opin Virol; 2011 Dec; 1(6):607-16. PubMed ID: 22440918
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of hepatitis C virus infection.
Thomas DL
Top Antivir Med; 2012; 20(1):5-10. PubMed ID: 22538244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
